Elevance Health Inc. (ELV)

Elevance and peers face earnings pressure from rising medical costs, driven by deferred care, expensive drugs, and persistent medical inflation. The segment has re-rated, and now offers good value. In...

UnitedHealth and Elevance battle rising costs, but scale, Optum, and Buffett's backing give UNH the edge in restoring investor trust.

Federal judge dismisses ELV's lawsuit challenging Medicare Advantage star ratings, leading to a $375M bonus loss tied to its star score.

A federal judge in Texas on Tuesday rejected Elevance Health's challenge of the U.S. government's calculation for the health insurer's star ratings for some of its government-backed Medicare plans aft...

ELV partners with NACHC to bring Food as Medicine into primary care, targeting nutritional insecurities and chronic disease.

INDIANAPOLIS--(BUSINESS WIRE)-- #ElevanceHealth--Elevance Health and the National Association of Community Health Centers (NACHC) are proud to announce the integration of Food as Medicine (FAM) progra...

ELV trims 2025 outlook as medical costs climb, but commercial growth and Carelon's momentum aim to steady performance.

ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.

These stocks have high upside potential through 2027. They're sitting at solid discounts and have good fundamentals.

Our focus for today includes BMY, REXR, and ELV. The trio offers a safe 4.2% dividend yield, an A- credit rating average, and a 27% weighted discount to fair value. Bristol-Myers Squibb possesses a li...